Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biosyngen OK’d to Start Phase II Trial of EBV Car-T Cell Therapy in US

publication date: Aug 14, 2024

Biosyngen, a Singapore-Guangzhou cell therapy company, has been approved to start a pivotal US Phase II trial of its Epstein-Barr-Virus-specific CAR-T cell therapy. The trial will enroll patients with relapsed/metastatic EBV-positive nasopharyngeal carcinoma. Biosyngen said BRG01 will be the first cell therapy to begin Phase II trials in both the US and China for the indication. BRG01 is also unusual because it is a cell therapy that targets a solid tumor. Patients were enrolled in a Phase I trial in the US and China earlier this year, and they have received a single BRG01 infusion. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here